Zydus Cadila, through its wholly-owned subsidiary Zydus Healthcare, has acquired six brands from global pharma major MSD and its subsidiaries. The brands include Deca-durabolin, Durabolin, Sustanon, Multiload, Sicastat and Axeten range, which fall in the men’s health, women’s health, cardiovascular and wound management therapy segments. The deal includes transfer of distribution and commercialization rights and assignment of trademarks of all the six brands to Zydus Healthcare in India.
As part of the deal, Organon (India), one of the legal subsidiaries through which MSD operates its business in India, has also transferred the distribution and commercialization rights for Deca-Durabolin and Durabolin to Zydus for Nepal.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1475.95 |
Dr. Reddys Lab | 5877.00 |
Cipla | 1505.55 |
Zydus Lifesciences | 1042.30 |
Lupin | 1622.00 |
View more.. |